Home » Stocks » RGNX


Stock Price: $37.05 USD 1.40 (3.93%)
Updated November 27, 1:00 PM EST - Market closed

Stock Price Chart

Key Info

Market Cap 1.39B
Revenue (ttm) 144.89M
Net Income (ttm) -91.47M
Shares Out 37.41M
EPS (ttm) -2.47
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day November 27
Last Price $37.05
Previous Close $35.65
Change ($) 1.40
Change (%) 3.93%
Day's Open 35.69
Day's Range 34.34 - 37.12
Day's Volume 117,976
52-Week Range 20.03 - 54.97

More Stats

Market Cap 1.39B
Enterprise Value 1.20B
Earnings Date (est) Mar 9, 2021
Ex-Dividend Date n/a
Shares Outstanding 37.41M
Float 33.67M
EPS (basic) -2.47
EPS (diluted) -2.47
FCF / Share -3.59
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 4.32M
Short Ratio 10.17
Short % of Float 12.83%
Beta 1.23
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 9.57
PB Ratio 3.21
Revenue 144.89M
Operating Income -105.91M
Net Income -91.47M
Free Cash Flow -134.05M
Net Cash 181.83M
Net Cash / Share 4.86
Gross Margin -67.08%
Operating Margin -73.09%
Profit Margin -63.10%
FCF Margin -92.52%
ROA -12.60%
ROE -20.69%
ROIC -24.40%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Forecasts

Analyst Ratings (8)

Buy 5
Overweight 1
Hold 2
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

(55.20% upside)
Current: $37.05
Target: 57.50
*Average 12-month price target from 8 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Revenue Growth-83.88%2002.42%126.48%-39.52%23.99%0.54%-
Gross Profit26.992098.683.736.095.115.76
Operating Income-14988.10-75.89-65.34-23.14-3.68-4.76
Net Income-94.7399.94-73.17-62.97-22.81-4.00-5.39
Shares Outstanding36.6933.4329.8826.419.172.642.32
Earnings Per Share-2.582.73-2.45-2.38-2.59-1.82-2.50
Operating Cash Flow-108105-57.99-48.56-22.52-2.40-3.01
Capital Expenditures-11.72-13.28-7.16-8.15-0.52--
Free Cash Flow-11991.37-65.15-56.71-23.04-2.40-3.01
Cash & Equivalents29832116189.781141.121.12
Total Debt11.305.85---2.40-
Net Cash / Debt28631516189.78114-1.281.12
Book Value450509183162217-18.29-13.92
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name REGENXBIO Inc.
Country United States
Employees 257
CEO Kenneth T. Mills

Stock Information

Ticker Symbol RGNX
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: RGNX
IPO Date September 17, 2015


REGENXBIO, a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's lead product candidate is RGX-314, which is in Phase I/IIa clinical trial for the treatment of wet age-related macular degeneration. It is also developing RGX-121 that is in Phase I/II clinical trial to treat mucopolysaccharidosis type II; RGX-111, which is in Phase I clinical trial for treating mucopolysaccharidosis type I; RGX-181 for the treatment of late infantile neuronal ceroid lipofuscinosis type II disease; and RGX-501, which is in Phase I/II clinical trials to treat homozygous familial hypercholesterolemia. REGENXBIO Inc. also licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies; and has a collaboration and license agreement with Neurimmune AG to develop vectorized antibodies for the treatment of neurodegenerative diseases. The company was formerly known as ReGenX Biosciences, LLC and changed its name to REGENXBIO Inc. in September 2014. REGENXBIO Inc. was founded in 2008 and is headquartered in Rockville, Maryland.